Boston Scientific (BSX)
(Delayed Data from NYSE)
$73.17 USD
-0.09 (-0.12%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $73.13 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth A Momentum B VGM
Boston Scientific (BSX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$72.78 | $90.00 | $60.00 | -0.66% |
Price Target
Based on short-term price targets offered by 23 analysts, the average price target for Boston Scientific comes to $72.78. The forecasts range from a low of $60.00 to a high of $90.00. The average price target represents a decline of 0.66% from the last closing price of $73.26.
Analyst Price Targets (23)
Broker Rating
Boston Scientific currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 24 brokerage firms. The current ABR compares to an ABR of 1.30 a month ago based on 23 recommendations.
Of the 24 recommendations deriving the current ABR, 19 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 79.17% and 12.5% of all recommendations. A month ago, Strong Buy made up 78.26%, while Buy represented 13.04%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 19 | 18 | 18 | 18 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.29 | 1.30 | 1.30 | 1.30 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/25/2024 | Robert W. Baird & Co. | David Rescott | Strong Buy | Strong Buy |
4/24/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
4/4/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
4/3/2024 | Argus Research Corp. | John M Eade | Not Available | Strong Buy |
3/6/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
2/1/2024 | Raymond James | Jayson T Bedford | Strong Buy | Strong Buy |
2/1/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Hold | Strong Buy |
1/26/2024 | Truist Securities | Richard Newitter | Strong Buy | Strong Buy |
1/19/2024 | BTIG | Marie Thibault | Strong Buy | Strong Buy |
9/21/2023 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.29 |
# of Recs in ABR | 24 |
Average Target Price | $72.78 |
LT Growth Rate | 12.50% |
Industry | Medical - Products |
Industry Rank by ABR | 140 of 252 |
Current Quarter EPS Est: | 0.58 |